Skip Navigation

Project Publications: University of Pennsylvania: Animal Models of Mesothelioma

Superfund Research Program

Animal Models of Mesothelioma

Project Leader: Joseph R. Testa (Fox Chase Cancer Center)
Co-Investigator: Rebecca A. Simmons
Grant Number: P42ES023720
Funding Period: 2014-2020

Project-Specific Links

Publications

2022

  • Pietrofesa RA, Chatterjee S, Kadariya Y, Testa JR, Albelda SM, Christofidou-Solomidou M. 2022. Synthetic secoisolariciresinol diglucoside (LGM2605) prevents asbestos-induced inflammation and genotoxic cell damage in human mesothelial cells. Int J Mol Sci 23(17):10085. doi:10.3390/ijms231710085 PMID:36077483 PMCID:PMC9456329

2020

  • Wallis SL, Emmett EA, Hardy R, Casper BB, Blanchon DJ, Testa JR, Menges CW, Gonneau C, Jerolmack DJ, Seiphoori A, Steinhorn G, Berry T. 2020. Challenging Global Waste Management - Bioremediation to Detoxify Asbestos. front environ sci 8:doi:10.3389/fenvs.2020.00020 PMID:33269243 PMCID:PMC7707057

2017

  • Cheung M, Menges CW, Testa JR. 2017. Germline and Somatic Mutations in Human Mesothelioma and Lessons from Asbestos-Exposed Genetically Engineered Mouse Models. Chapter 8 in: Asbestos and Mesothelioma. Springer International Publishing, pp.175-195.
  • Cheung M, Testa JR. 2017. BAP1, a tumor suppressor gene driving malignant mesothelioma. Transl Lung Cancer Res 6(3):270-278. doi:10.21037/tlcr.2017.05.03 PMID:28713672 PMCID:PMC5504107
  • Testa JR. 2017. Malignant Mesothelioma: An Asbestos Legacy. Chapter 1 in: Asbestos and Mesothelioma. Springer International Publishing, pp.1-9.

2016

  • Kadariya Y, Cheung M, Xu J, Pei J, Sementino E, Menges CW, Cai KQ, Rauscher FJ, Klein-Szanto AJ, Testa JR. 2016. Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations. Cancer Res 76(9):2836-2844. doi:10.1158/0008-5472.CAN-15-3371 PMID:26896281 PMCID:PMC4873414
  • Kadariya Y, Menges CW, Talarchek J, Cai KQ, Klein-Szanto AJ, Pietrofesa RA, Christofidou-Solomidou M, Cheung M, Mossman BT, Shukla A, Testa JR. 2016. Inflammation-related IL1β/IL1R signaling promotes the development of asbestos-induced malignant mesothelioma. Cancer Prev Res (Phila) 9(5):406-414. doi:10.1158/1940-6207.CAPR-15-0347 PMID:26935421 PMCID:PMC4854753
  • Ohar J, Cheung M, Talarchek J, Howard S, Howard T, Hesdorffer M, Peng H, Rauscher FJ, Testa JR. 2016. Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer. Cancer Res 76(2):206-215. doi:10.1158/0008-5472.CAN-15-0295 PMID:26719535 PMCID:PMC4715907

2015

  • Cheung M, Kadariya Y, Pei J, Talarchek J, Facciolo F, Visca P, Righi L, Cozzi I, Testa JR, Ascoli V. 2015. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation. Cancer Genet 208(10):502-507. doi:10.1016/j.cancergen.2015.07.004 PMID:26364129 PMCID:PMC4608746
  • Cheung M, Kadariya Y, Talarchek J, Pei J, Ohar J, Kayaleh O, Testa JR. 2015. Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction. Cancer Lett 369(2):261-265. doi:10.1016/j.canlet.2015.09.011 PMID:26409435 PMCID:PMC4634709
  • Karla N, Zhang J, Thomas A, Xi L, Talarchek J, Burkett S, Tsokos MG, Chen Y, Raffeld M, Miettinen M, Pastan I, Testa JR, Hassan R, Cheung M. 2015. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma. BMC Cancer 15:376. doi:10.1186/s12885-015-1362-2 PMID:25952750 PMCID:PMC4431029
  • Yabas M, Elliott H, Hoyne GF. 2015. The role of alternative splicing in the control of immune homeostasis and cellular differentiation. Int J Mol Sci 17(1):doi:10.3390/ijms17010003 PMID:26703587 PMCID:PMC4730250
Back
to Top